AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

AbbVie's Latest FDA Approval Is Its Most Important Immunology Win Since Humira

Source: 
Motley Fool
snippet: 

On Friday, AbbVie added another key FDA approval with a positive decision for Rinvoq (upadacitinib) in treating rheumatoid arthritis. This latest FDA approval is AbbVie's biggest regulatory victory so far this year. And it just might be the most important immunology win for the company since Humira.